FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to corticosteroids or cannot tolerate a corticosteroid taper. The regulatory decision establishes Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic for PMR, giving rheumatologists an alternative to long-term steroid therapy backed by over a decade of clinical experience across immune-mediated diseases. Addressing High Relapse Rates And Steroid Risks In PMR Roughly 966,000 people in the U.S. live with PMR, a common inflammatory disorder that primarily strikes adults aged 50 and older. Read Also: Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit The condition triggers acute pain and stiffness in the shoulders, neck, and hips, while fatigue, limited mobility, and fear of relapse heavily diminish daily quality of life. Physicians typically rely on long-term steroids as the standard of care, yet relapses hit up to 40% of patients during their first year. Prolonged steroid regimens also elevate the risk of severe complications, including osteoporosis, cardiovascular disease, and diabetes. Phase 3 REPLENISH Trial Demonstrates Double Remission Rates The FDA based its approval on the global Phase 3 REPLENISH study. Researchers assigned participants to receive Cosentyx 300 mg, Cosentyx 150 mg, or a placebo alongside a 24-week steroid taper regimen. The New England Journal of Medicine published the data, which investigators simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress. The study met its primary endpoint at week 52 following the 24-week steroid taper, as adults taking Cosentyx 150 mg achieved sustained remission at double the rate of placebo recipients, at 40.5% versus 20.5%. Key secondary endpoints tracked complete sustained remission at week 52, adjusted annual cumulative steroid doses, and the time until patients first required escape or rescue therapy through week 52. NVS Price Action: Novartis shares were down 1.07% at $158.49 during premarket trading on Tuesday, according to Benzinga Pro data. Read Also: 121-Year-Old REO Nameplate Has Officially Been Revived — Its First Vehicle Targets Jeff Bezos-Backed Slate Auto: Here's What You Need to Know Photo: Shutterstock
\